Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function

Objective The intestinal microbiome affects the prevalence and pathophysiology of a variety of diseases ranging from inflammation to cancer. A reduced taxonomic or functional diversity of the microbiome was often observed in association with poorer health outcomes or disease in general. Conversely, factors or manifest diseases that determine the long-term stability or instability of the microbiome are largely unknown. We aimed to identify disease-relevant phenotypes associated with faecal microbiota (in-)stability. Design A total of 2564 paired faecal samples from 1282 participants of the population-based Study of Health in Pomerania (SHIP) were collected at a 5-year (median) interval and microbiota profiles determined by 16S rRNA gene sequencing. The changes in faecal microbiota over time were associated with highly standardised and comprehensive phenotypic data to determine factors related to microbiota (in-)stability. Results The overall microbiome landscape remained remarkably stable over time. The greatest microbiome instability was associated with factors contributing to metabolic syndrome such as fatty liver disease and diabetes mellitus. These, in turn, were associated with an increase in facultative pathogens such as Enterobacteriaceae or Escherichia/Shigella. Greatest stability of the microbiome was determined by higher initial alpha diversity, female sex, high household income and preserved exocrine pancreatic function. Participants who newly developed fatty liver disease or diabetes during the 5-year follow-up already displayed significant microbiota changes at study entry when the diseases were absent. Conclusion This study identifies distinct components of metabolic liver disease to be associated with instability of the intestinal microbiome, increased abundance of facultative pathogens and thus greater susceptibility toward dysbiosis-associated diseases.

[1]  Gavin M Douglas,et al.  PICRUSt2 for prediction of metagenome functions , 2020, Nature Biotechnology.

[2]  Patrice D Cani,et al.  Mediterranean diet, gut microbiota and health: when age and calories do not add up! , 2020, Gut.

[3]  H. Völzke,et al.  Helicobacter pylori infection associates with fecal microbiota composition and diversity , 2019, Scientific Reports.

[4]  C. Huttenhower,et al.  Obese Individuals with and without Type 2 Diabetes Show Different Gut Microbial Functional Capacity and Composition. , 2019, Cell host & microbe.

[5]  G. Homuth,et al.  A structured weight loss program increases gut microbiota phylogenetic diversity and reduces levels of Collinsella in obese type 2 diabetics: A pilot study , 2019, PloS one.

[6]  H. Völzke,et al.  Impaired Exocrine Pancreatic Function Associates With Changes in Intestinal Microbiota Composition and Diversity. , 2019, Gastroenterology.

[7]  Benjamin M Hillmann,et al.  US Immigration Westernizes the Human Gut Microbiome , 2018, Cell.

[8]  Jie Peng,et al.  A comparison of pyogenic liver abscess in patients with or without diabetes: a retrospective study of 246 cases , 2018, BMC Gastroenterology.

[9]  B. Schnabl,et al.  Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease , 2018, Gut.

[10]  M. Rupnik,et al.  Interactions Between Clostridioides difficile and Fecal Microbiota in in Vitro Batch Model: Growth, Sporulation, and Microbiota Changes , 2018, Front. Microbiol..

[11]  Patrice D Cani.  Human gut microbiome: hopes, threats and promises , 2018, Gut.

[12]  Shiraz A. Shah,et al.  Meta-analysis of human genome-microbiome association studies: the MiBioGen consortium initiative , 2018, Microbiome.

[13]  H. Völzke,et al.  Functional abdominal pain and discomfort (IBS) is not associated with faecal microbiota composition in the general population , 2018, Gut.

[14]  T. Spector,et al.  The fecal metabolome as a functional readout of the gut microbiome , 2018, Nature Genetics.

[15]  Patrice D Cani,et al.  The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice , 2018, Diabetologia.

[16]  C. Knauf,et al.  Gut Microbes and Health: A Focus on the Mechanisms Linking Microbes, Obesity, and Related Disorders , 2018, Obesity.

[17]  U. Ijaz,et al.  Fecal Enterobacteriales enrichment is associated with increased in vivo intestinal permeability in humans , 2018, Physiological reports.

[18]  D. Gouma,et al.  Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis , 2018, Journal of hepato-biliary-pancreatic sciences.

[19]  M. Kimura,et al.  Gut microbiota-mediated generation of saturated fatty acids elicits inflammation in the liver in murine high-fat diet-induced steatohepatitis , 2017, BMC Gastroenterology.

[20]  Markus Krummenacker,et al.  The MetaCyc database of metabolic pathways and enzymes , 2017, Nucleic acids research.

[21]  Pascal G. P. Martin,et al.  Dietary oleic acid regulates hepatic lipogenesis through a liver X receptor-dependent signaling , 2017, PloS one.

[22]  David Torrents,et al.  Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug , 2017, Nature Medicine.

[23]  P. Worley,et al.  Orai1-Mediated Antimicrobial Secretion from Pancreatic Acini Shapes the Gut Microbiome and Regulates Gut Innate Immunity. , 2017, Cell metabolism.

[24]  H. Tilg,et al.  Gut microbiome and liver diseases , 2016, Gut.

[25]  J. Clemente,et al.  The microbiome in early life: implications for health outcomes , 2016, Nature Medicine.

[26]  R. Osawa,et al.  Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study , 2016, BMC Microbiology.

[27]  Paul J. McMurdie,et al.  DADA2: High resolution sample inference from Illumina amplicon data , 2016, Nature Methods.

[28]  H. Tilg,et al.  Altered intestinal microbiota as a major driving force in alcoholic steatohepatitis , 2016, Gut.

[29]  R. Milo,et al.  Revised Estimates for the Number of Human and Bacteria Cells in the Body , 2016, bioRxiv.

[30]  Jingyuan Fu,et al.  Proton pump inhibitors affect the gut microbiome , 2015, Gut.

[31]  S. Hultgren,et al.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options , 2015, Nature Reviews Microbiology.

[32]  M. Peters,et al.  Identification of genetic loci associated with Helicobacter pylori serologic status. , 2013, JAMA.

[33]  Patrice D Cani,et al.  Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity , 2012, Gut microbes.

[34]  J. Clemente,et al.  Human gut microbiome viewed across age and geography , 2012, Nature.

[35]  W. Rathmann,et al.  Cohort profile: the study of health in Pomerania. , 2011, International journal of epidemiology.

[36]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[37]  T. van de Wiele,et al.  Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability , 2009, Gut.

[38]  R. Bibiloni,et al.  Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet–Induced Obesity and Diabetes in Mice , 2008, Diabetes.

[39]  C. Knauf,et al.  Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia , 2007, Diabetologia.

[40]  J. Ferrières,et al.  Metabolic Endotoxemia Initiates Obesity and Insulin Resistance , 2007, Diabetes.

[41]  Chien-Chang Lee,et al.  Epidemiology and Prognostic Determinants of Patients with Bacteremic Cholecystitis or Cholangitis , 2007, The American Journal of Gastroenterology.

[42]  B. Eikmanns,et al.  Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-κB activation , 2006 .

[43]  U. John,et al.  Association Between Behavior-Dependent Cardiovascular Risk Factors and Asymptomatic Carotid Atherosclerosis in a General Population , 2002, Stroke.

[44]  Jonathan M. Levine,et al.  Elton revisited: a review of evidence linking diversity and invasibility , 1999 .

[45]  A. Döring,et al.  Validation of a short qualitative food frequency list used in several German large scale surveys , 1998, Zeitschrift fur Ernahrungswissenschaft.

[46]  R. Rice.  Mediterranean diet , 1994, The Lancet.

[47]  E. Parks,et al.  Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. , 2015, The American journal of clinical nutrition.

[48]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[49]  M. Falagas,et al.  Citrobacter infections in a general hospital: characteristics and outcomes , 2008, European Journal of Clinical Microbiology & Infectious Diseases.

[50]  P. Legendre,et al.  vegan : Community Ecology Package. R package version 1.8-5 , 2007 .

[51]  B. Eikmanns,et al.  Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. , 2006, World journal of gastroenterology.